The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs

Oman Journal of Ophthalmology

Volumn 9, Issue 1, 2016, Pages 44-48

  Bakbak, Berker ^a   Ozturk, Banu ^a   Gonul, Saban ^a   Gedik, Sansal ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Antivascular endothelial growth factor treatment; bevacizumab; diabetic retinopathy; macular edema; ranibizumab

Indexed keywords

EID: 84958961749     PISSN: 0974620X     EISSN: 09747842     Source Type: Journal    
DOI: 10.4103/0974-620X.176100     Document Type: Article

References (24)

1. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review. BMJ 2012;345:e5182
2. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: A systematic review. Br J Ophthalmol 2012;96:167-78
3. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther 2011;27:373-7
4. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15-27
5. Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: An update. Indian J Ophthalmol 2008;56:178-88
6. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-12
7. Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30
8. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454-9
9. Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers MB 3rd, Morales-Caton V, Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 2009;29:20-6
10. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: A case report. Ann Acad Med Singapore 2008;37:591-3
11. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009;13:400-2
12. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:16951-15
13. Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina 2011;31:1871-6
14. Selim KM, Sahan D, Muhittin T, Osman C, Mustafa O. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol 2010;58:375-9
15. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
16. Scartozzi R, Chao JR, Walsh AC, Eliott D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:1229
17. Sharma A, Sheth J, Madhusudan RJ, Sundaramoorthy SK. Effect of intravitreal dexamethasone implant on the contralateral eye: A case report. Retin Cases Brief Rep 2013;7:217-9
18. Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I, et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009;223:383-9
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82
20. Gamulescu MA, Helbig H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 2010;26:213-6
21. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 2010;149:939-946.e1
22. Martin DF, Maguire MG. Treatment choice for diabetic macular edema. N Engl J Med 2015;372:1260-1
23. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014;98:1636-41
24. Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 2013;29:728-32